Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ThromboGenics Appoints Dr David Guyer to its Board of Directors

Published: Monday, December 23, 2013
Last Updated: Sunday, December 22, 2013
Bookmark and Share
Dr Guyer is currently the Co-Founder and Chief Executive Officer of Ophthotech Corporation.

ThromboGenics NV has announced the appointment of Dr David Guyer to its Board of Directors.

Dr Guyer M.D. is a long standing member of the US retina community and is currently the Co-Founder and Chief Executive Officer of Ophthotech Corporation and also serves as Chairman of its board of directors.

Ophthotech Corporation is a public biopharmaceutical company focusing on discovering, developing and commercializing first-in-class therapies for the treatment of major ophthalmic diseases.

Ophthotech’s lead compound Fovista (previously known as E10030) is being evaluated in a Phase III trial for use in combination with anti-VEGF therapy for the treatment of patients with wet AMD. Ophthotech listed on Nasdaq in September 2013, raising $192 million in its IPO.

Dr. Guyer is also on the Boards of Allocure and Panoptica.

Dr.Guyer co-founded and served as CEO and a Director of Eyetech Pharmaceuticals, Inc., where he led the company through private, public and corporate financings, and oversaw the rapid development and successful commercialization of Macugen® (pegaptanib sodium), the first FDA-approved anti-VEGF pharmacological treatment for the treatment of wet AMD. Eyetech was acquired by OSI Pharmaceuticals Inc for $935 million in 2005.

Staf Van Reet, the Chairman of ThromboGenics commenting on today’s announcement said, “I am delighted to welcome David to the Board. His decades of success in the ophthalmology space both in drug development and commercialization, particularly in the US, will be extremely valuable to ThromboGenics. We are continuing to maximize the potential of JETREA® for the treatment of symptomatic VMA and further develop our emerging portfolio of therapies for the treatment of diabetes-related retinal diseases.”

Dr Guyer has also had a successful career in academic medicine as Professor and Chairman of the Department of Ophthalmology at New York University School of Medicine. Dr. Guyer received his Bachelor of Science (B.S.) degree from Yale College summa cum laude and his medical degree (M.D.) from Johns Hopkins Medical School. He completed his ophthalmology residency at Wilmer Ophthalmological Institute at Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.

Dr David Guyer, commenting on his appointment, said, “ThromboGenics has made significant progress in recent years, leading to the introduction of JETREA® in the US early in 2013. I am happy to be joining the board of this dynamic company as it works to create a new treatment paradigm for patients with early stage symptomatic VMA.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ThromboGenics and VIB Launch New Oncology Company
Oncurious NV to develop TB-403 for pediatric brain tumors.
Tuesday, April 14, 2015
ThromboGenics Initiates Major Post-Marketing Patient Trial with JETREA® in the US
ORBIT study designed to generate further data on the “real world” use of JETREA®.
Thursday, March 06, 2014
ThromboGenics Business Update
US sales through end of April 2013 have exceeded $10 million.
Monday, May 27, 2013
ThromboGenics Receives Positive CHMP Opinion for JETREA®
Positive opinion clears the way for the potential EMA approval of JETREA® as the first pharmacological option for the treatment of VMT, including when associated with macular hole of diameter less than or equal to 400 microns.
Wednesday, April 24, 2013
ThromboGenics NV - Business Update
Company to build a first-class US commercial organization to launch JETREA in January 2013.
Friday, November 09, 2012
ThromboGenics NV - Business Update
ThromboGenics sign an important strategic deal with Alcon.
Monday, October 22, 2012
U.S. FDA Approves ThromboGenics’ JETREA® (Ocriplasmin)
JETREA® is the first pharmacological agent approved for the treatment of symptomatic VMA.
Thursday, October 18, 2012
ThromboGenics Announces Publication of New England Journal of Medicine Paper
Paper highlights that ocriplasmin is superior to placebo in resolving VMT and closing macular holes in patients with VMA.
Saturday, September 15, 2012
ThromboGenics and BioInvent Announce Results from Phase IIb VTE Prevention Study with TB-402
All further development of TB-402 will be stopped.
Thursday, July 05, 2012
ThromboGenics and BioInvent Complete Enrolment of Phase IIb Trial with TB-402 Ahead of Schedule
The companies announced they have completed the enrolment of a 632-patient Phase IIb trial with their long-acting anticoagulant TB-402 (factor VIII inhibitor).
Friday, December 16, 2011
ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for VMA
Highly significant trial result demonstrates the potential of microplasmin in the treatment of retinal disease.
Monday, April 26, 2010
ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
ThromboGenics NV announces results of a Phase IIa trial evaluating microplasmin intravitreal injection for the treatment of Diabetic Macular Edema (MIVI II DME). The data from this trial were presented at the ASRS (American Society of Retina Specialists) Conference in New York on 3 October, 2009 by Professor Peter Stalmans, University Hospitals Leuven, Belgium.
Friday, October 09, 2009
ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of DME
The MIVI II DME trial is a Phase II clinical trial evaluating the safety and initial efficacy of intravitreal microplasmin for the treatment of DME patients.
Monday, March 09, 2009
Scientific News
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Benefits of Early Antiretroviral Therapy in HIV Infection
Scientists have explored the clinical importance of starting treatment early in individuals suffering with HIV.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!